Efficiency and safety of pemetrexed and cisplatin therapy in the adenocarcinoma and large cell cancer types of advanced non-small cell lung cancer (NSCLC)
Abstract
The report contains results of efficacy and Scifety data analysis of pemetrexed/cisplatin first-line treatment in patients with advanced/metastatic non-small cell lung cancer (adenocarcinoma cind large cell carcinoma histologic types) retrieved from the TULUNG patient registry, which monitors the use of expensive NSCLC treatment in Czech centers providing comprehensive care in lung oncology. In a sample of 112 patients (77 with completed treatment) after treatment lasting for an average of 3-4 cycles, a disease control rate of 61.1 % was achieved in evaluable patients with completed treatment.
In the studied population, the median progression-free survival was 3.0 months and the median overall survival was 13.5 months. The treatment was very well tolerated and had to be discontinued due to adverse events in only two patients.
The most frequent therapy-related adverse events were hematologic toxicities: neutropenia (11.6 %), anemia (8.0 %) and leukopenia (4.5 %). No adverse effects were reported in 73 % of the patients receiving treatment.
This non-interventional observation demonstrated good efficacy and tolerability of pemetrexed/cisplatin combination in first-line treatment of lung adenocarcinoma and large cell lung carcinoma in common clinical practice in the Czech Republic.